Jak2 Tyrosine Kinase and Cancer: How Good Cells Get HiJAKed

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Jak2 Tyrosine Kinase and Cancer: How Good Cells Get HiJAKed

Anti-Cancer Agents in Medicinal Chemistry, 7(6): 643-650.

Author(s): Michael D. Godeny and Peter P Sayeski.

Affiliation: Department of Physiology and Functional Genomics, University of Florida College of Medicine, P.O.Box 100274, Gainesville, FL 32610, USA.


Cloned in 1992, Jak2 tyrosine kinase has emerged as a critical molecule in mammalian development, physiology, and disease. Here, we will review the early history of Jak2 as it pertains to its role in classical cellular signaling. We also review how specific structural determinants within Jak2 dictate its overall function. Finally, we will review relatively recent literature as it pertains to the role of Jak2 in neoplastic growth as well as the identification of novel Jak2 inhibitors. It is our hope that by reviewing these specific areas, we will have a better understanding of the role of Jak2 in cancer, and in turn, we may have a better idea as to how to block aberrant Jak2 function.


Jak2, tyrosine kinase, cancer, signal transduction, gene transcription.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 7
Issue Number: 6
First Page: 643
Last Page: 650
Page Count: 8
DOI: 10.2174/187152007782330105
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science